This summer, the FDA gave a favorable nod to several ophthalmic technologies. The succession of these approvals—and, in some cases, the pace at which they were obtained—have prompted many in ophthalmology to question whether we could be entering a new chapter in regulation. Time will tell, but for now, we can enjoy having access to these newly approved treatment options and hope that the trend continues.
Raindrop Near Vision Inlay
In June, the FDA approved the Raindrop Near Vision Inlay (ReVision Optics) for the surgical correction of presbyopia. The Raindrop joins the Kamra (AcuFocus) in our arsenal of corneal inlays, which could, at some point, also include the Flexivue Microlens (Presbia), in use by our international colleagues. As we gain access to these devices, it is important to understand the intricacies of these procedures, including the differences between implantation in a pocket (Kamra) or under a flap (Raindrop), and to remain up to date on advances in surgical techniques.
This July, the FDA approved Shire’s Xiidra (lifitegrast ophthalmic solution 5%), making it the first prescription pharmacologic treatment option for dry eye disease to gain approval in more than a decade. Xiidra is a twice-daily eye drop solution indicated for the treatment of both signs and symptoms of dry eye disease. Bob Dempsey, Vice President and Head of Ophthalmics, recently weighed in on the significance of this approval.
Most recently, Abbott Medical Optics received FDA approval of its Tecnis Symfony and Tecnis Symfony Toric IOLs. The Symfony looks similar to the Tecnis Multifocal IOLs, with the only visible difference being the number of diffractive rings (Symfony has 9 rings, whereas ZKB00 has 15, ZLB00 has 18, and ZMB00 has 22). We have been seeing positive results with the Symfony from our colleagues in Europe, so it will be exciting to see the quality of outcomes achieved on the home front.